Skip to main content
SpringerLink
Log in

Nilotinib, dasatinib or imatinib in CML: no clear winner

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nilotinib, dasatinib or imatinib in CML: no clear winner. Pharmacoecon. Outcomes News 656, 7–8 (2012). https://doi.org/10.2165/00151234-201206560-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-201206560-00009

Keywords

Search

Navigation